Short-term outcomes of COVID-19 and risk factors for progression
Open Access
- 20 April 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (5), 2000990
- https://doi.org/10.1183/13993003.00990-2020
Abstract
With a median follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe, 66.7% critical COVID-19. A neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male gender, and comorbidity were associated with progression.Funding Information
- Guangzhou Medical University (Clinical Research Foundation 2017-160, Incubative Project for Innovation Team 2017-159)
This publication has 7 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysisEuropean Respiratory Journal, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyThe Lancet, 2020
- Department of ErrorThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020